NRx Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017
Net Income	-30.16	-39.75	-348.89	-51.78	-6.73	0.07	-0.11
Depreciation & Amortization	0.01	0	0	0	0	0	0
Share-Based Compensation	0.39	3.63	61.62	0.73	0.93	0	0
Other Operating Activities	8.1	-3.63	-6.26	48.78	0.25	-0.54	-0.03
Operating Cash Flow	-21.66	-39.76	-37.7	-2.27	-5.54	-0.47	-0.14
Capital Expenditures	-0	-0.01	-0.01	-0	-0	0	0
Change in Investments	0	0	0	0	0	-0.65	-69
Other Investing Activities	-	-	-	-	-	1.3	-
Investing Cash Flow	-0	-0.01	-0.01	-0	-0	0.65	-69
Share Issuance / Repurchase	8.12	22.71	64.73	2.58	5.8	0	70.03
Debt Issued / Paid	-3.09	9.5	-1.28	0.62	0	0.69	0
Other Financing Activities	1.17	-	-	0.05	-	-0.01	-0.44
Financing Cash Flow	6.2	32.21	63.46	3.25	5.8	0.68	69.59
Net Cash Flow	-15.46	-7.55	25.75	0.98	0.26	-0.44	0.45
Free Cash Flow	-21.66	-39.77	-37.71	-2.27	-5.55	-0.47	-0.14
Free Cash Flow Per Share	-2.86	-6.05	-8.04	-0.66	-5.19	-1.81	-0.72

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).